Investing
CEO Of The Year Nominees: 8) Kevin W. Scharer Of Amgen (AMGN)
Published:
24/7 Wall St. will name its annual CEO of the Year next week. The executive will be picked from a field of ten which we will profile this week
The CEOs are chosen on the basis of their company’s stock market and financial performances compared with their own industry groups and all large companies traded on US markets. Only firms with market caps of more than $5 billion were considered. 24/7 reviewed revenue growth, operating margins, balance sheets, return on assets, and return on equity.
At Amgen’s (AMGN) recent "sit down" with analysts, the biotech company said that "Over the next five years we could have three more drugs achieve blockbuster status: Sensipar (cinacalcet), denosumab for osteoporosis and denosumab for cancer-related indications." A tall order, but Amgen has delivered before.
In the last quarter, backing out charges, Amgen reported adjusted earnings of $1.23 a share versus $1.08 share a year earlier. Revenue rose 7% to $3.88 billion. Both numbers beat Wall St. estimates. Over the last year, AMGN shares are up 5% compared with a 35% drop in the DJIA.
Amgen has faced significant challenges in 2007 and 2008. Epogen and Aranesp, two of the firm’s important products, faced FDA challenges on safety. But, as a Morningstar analyst points out, Amgen markets four of the top 10 best-selling biologics in the world and has continued to be the strongest firms in the industry.
Amgen could have had a very rough year. Kevin Scharer has kept R&D yield ahead of challenges from generics and rocky issues with the company’s products.
Douglas A. McIntyre
The #1 Thing to Do Before You Claim Social Security (Sponsor)
Choosing the right (or wrong) time to claim Social Security can dramatically change your retirement. So, before making one of the biggest decisions of your financial life, it’s a smart idea to get an extra set of eyes on your complete financial situation.
A financial advisor can help you decide the right Social Security option for you and your family. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you.
Click here to match with up to 3 financial pros who would be excited to help you optimize your Social Security outcomes.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
